{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:16:54Z","timestamp":1789647414139,"version":"4.0.0"},"reference-count":39,"publisher":"American Veterinary Medical Association (AVMA)","issue":"S1","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2022,1,15]]},"abstract":"Abstract<\/jats:title>\n \n OBJECTIVE<\/jats:title>\n To compare effectiveness of maropitant and ondansetron in preventing preoperative vomiting and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate.<\/jats:p>\n <\/jats:sec>\n \n ANIMALS<\/jats:title>\n 88 dogs owned by rescue organizations.<\/jats:p>\n <\/jats:sec>\n \n PROCEDURES<\/jats:title>\n Dogs received maropitant (n = 29) or ondansetron (28) PO 2 hours prior to premedication or did not receive an antiemetic (31; control). Dogs were evaluated for vomiting, nausea, and severity of nausea (scored for 6 signs) for 15 minutes following premedication with hydromorphone, acepromazine, and glycopyrrolate.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n A significantly lower percentage of dogs vomited after receiving maropitant (3\/29 [10%]), compared with control dogs (19\/31 [62%]) and dogs that received ondansetron (15\/28 [54%]). A significantly lower percentage of dogs appeared nauseated after receiving maropitant (3\/29 [10%]), compared with control dogs (27\/31 [87%]) and dogs that received ondansetron (14\/28 [50%]), and a significantly lower percentage of dogs appeared nauseated after receiving ondansetron, compared with control dogs. Nausea severity scores for hypersalivation, lip licking, hard swallowing, and hunched posture were significantly lower for dogs that received maropitant than for control dogs, and scores for hypersalivation, lip licking, and hard swallowing were significantly lower for dogs that received ondansetron than for control dogs.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS AND CLINICAL RELEVANCE<\/jats:title>\n Oral administration of maropitant 2 hours prior to premedication with hydromorphone reduced the incidence of vomiting and the incidence and severity of nausea in healthy dogs. Oral administration of ondansetron reduced the incidence and severity of nausea but not the incidence of vomiting.<\/jats:p>\n <\/jats:sec>","DOI":"10.2460\/javma.21.02.0082","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T16:26:26Z","timestamp":1639585586000},"page":"S40-S45","source":"Crossref","is-referenced-by-count":13,"title":["Effectiveness of orally administered maropitant and ondansetron in preventing preoperative emesis and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate"],"prefix":"10.2460","volume":"260","author":[{"given":"Jasper E.","family":"Burke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka S.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah C.","family":"Silverstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"key":"B1","series-title":"J Am Vet Med Assoc","first-page":"1101","article-title":"Effects of hydromorphone or oxymorphone, with or without acepromazine, on preanesthetic sedation, physiologic values, and histamine release in dogs","volume":"218","year":"2001","unstructured":"Smith LJ, Yo JK, Bjorling DE, et al. Effects of hydromorphone or oxymorphone, with or without acepromazine, on preanesthetic sedation, physiologic values, and histamine release in dogs. J Am Vet Med Assoc. 2001;218:1101\u20131105."},{"key":"B2","series-title":"Can Vet J","first-page":"135","article-title":"Hydromorphone: a cost-effective alternative to the use of oxymorphone","volume":"41","year":"2000","unstructured":"Pettifer G, Dyson D. Hydromorphone: a cost-effective alternative to the use of oxymorphone. Can Vet J. 2000;41:135\u2013137."},{"key":"B3","series-title":"J Vet Pharmacol Ther","first-page":"516","article-title":"Comparison of plasma histamine levels after intravenous administration of hydromorphone and morphine in dogs","volume":"30","year":"2007","unstructured":"Guedes AGP, Papich MG, Rude EP, et al. Comparison of plasma histamine levels after intravenous administration of hydromorphone and morphine in dogs. J Vet Pharmacol Ther. 2007;30:516\u2013522."},{"issue":"1","key":"B4","series-title":"Vet Anaesth Analg","first-page":"28","article-title":"Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone","volume":"40","year":"2013","unstructured":"Hay Kraus BL. Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone. Vet Anaesth Analg. 2013;40(1):28\u201334."},{"key":"B5","series-title":"J Am Vet Med Assoc","first-page":"1015","article-title":"Effect of dosing interval on efficacy of maropitant for prevention of hydromorphone-induced vomiting and signs of nausea in dogs","volume":"245","year":"2014","unstructured":"Hay Kraus BL. Effect of dosing interval on efficacy of maropitant for prevention of hydromorphone-induced vomiting and signs of nausea in dogs. J Am Vet Med Assoc. 2014;245:1015\u20131020."},{"key":"B6","series-title":"J Vet Intern Med","first-page":"1414","article-title":"Effects of maropitant citrate or acepromazine on the incidence of adverse events associated with hydromorphone premedication in dogs","volume":"28","year":"2014","unstructured":"Claude AK, Dedeaux A, Chiavaccini L, et al. Effects of maropitant citrate or acepromazine on the incidence of adverse events associated with hydromorphone premedication in dogs. J Vet Intern Med. 2014;28:1414\u20131417."},{"key":"B7","series-title":"Veterinary Pharmacology and Therapeutics","first-page":"281","article-title":"Opioid analgesic drugs","year":"2018","unstructured":"KuKanich B, Papich MG. Opioid analgesic drugs. In: Riviere JE, Papich MG, eds. Veterinary Pharmacology and Therapeutics. 10th ed. Wiley Blackwell; 2018:281\u2013323."},{"key":"B8","series-title":"Vet Anaesth Analg","first-page":"40","article-title":"Effects of acepromazine on the incidence of vomiting associated with opioid administration in dogs","volume":"31","year":"2004","unstructured":"Valverde A, Cantwell S, Hernandez J, et al. Effects of acepromazine on the incidence of vomiting associated with opioid administration in dogs. Vet Anaesth Analg. 2004;31:40\u201345."},{"key":"B9","series-title":"Eur J Pharmacol","first-page":"143","article-title":"Emetic and antiemetic effects of opioids in the dog","volume":"128","year":"1986","unstructured":"Blancquaert JP, Lefebvre RA, Willems JL. Emetic and antiemetic effects of opioids in the dog. Eur J Pharmacol. 1986;128:143\u2013150."},{"key":"B10","series-title":"J Vet Emerg Crit Care (San Antonio)","first-page":"319","article-title":"Potential risks, prognostic indicators, and diagnostic and treatment modalities affecting survival in dogs with presumptive aspiration pneumonia: 125 cases (2005\u20132008)","volume":"20","year":"2010","unstructured":"Tart KM, Babski DM, Lee JA. Potential risks, prognostic indicators, and diagnostic and treatment modalities affecting survival in dogs with presumptive aspiration pneumonia: 125 cases (2005\u20132008). J Vet Emerg Crit Care (San Antonio). 2010;20:319\u2013329."},{"key":"B11","series-title":"J Am Vet Med Assoc","first-page":"1748","article-title":"Etiology and clinical outcome in dogs with aspiration pneumonia: 88 cases (2004\u20132006)","volume":"233","year":"2008","unstructured":"Kogan DA, Johnson LR, Sturges BK, et al. Etiology and clinical outcome in dogs with aspiration pneumonia: 88 cases (2004\u20132006). J Am Vet Med Assoc. 2008;233:1748\u20131755."},{"key":"B12","series-title":"J Vet Emerg Crit Care (San Antonio)","first-page":"176","article-title":"Post-operative pulmonary complications in dogs undergoing laparotomy: frequency, characterization and disease-related risk factors","volume":"16","year":"2006","unstructured":"Alwood AJ, Brainard BM, LaFond E, et al. Post-operative pulmonary complications in dogs undergoing laparotomy: frequency, characterization and disease-related risk factors. J Vet Emerg Crit Care (San Antonio). 2006;16:176\u2013183."},{"key":"B13","series-title":"Vet Surg","first-page":"432","article-title":"Pneumonia after intracranial surgery in dogs","volume":"30","year":"2001","unstructured":"Fransson BA, Bagley RS, Gay JM, et al. Pneumonia after intracranial surgery in dogs. Vet Surg. 2001;30:432\u2013439."},{"key":"B14","series-title":"Vet Anaesth Analg","first-page":"127","article-title":"Prevalence and risk factors for canine post-anesthetic aspiration pneumonia (1999\u20132009): a multi-center study","volume":"41","year":"2014","unstructured":"Ovbey DH, Wilson DV, Bednarski RM, et al. Prevalence and risk factors for canine post-anesthetic aspiration pneumonia (1999\u20132009): a multi-center study. Vet Anaesth Analg. 2014;41:127\u2013136."},{"key":"B15","series-title":"Front Vet Sci","first-page":"264","article-title":"Assessment of dog owner concern regarding peri-operative nausea and vomiting and willingness to pay for antiemetic treatment","volume":"6","year":"2019","unstructured":"Hay Kraus BL, Cazlan C. Assessment of dog owner concern regarding peri-operative nausea and vomiting and willingness to pay for antiemetic treatment. Front Vet Sci. 2019;6:264."},{"issue":"10","key":"B16","series-title":"J Am Vet Med Assoc","first-page":"1164","article-title":"Efficacy of orally administered maropitant citrate in preventing vomiting associated with hydromorphone administration in dogs","volume":"244","year":"2014","unstructured":"Hay Kraus BL. Efficacy of orally administered maropitant citrate in preventing vomiting associated with hydromorphone administration in dogs. J Am Vet Med Assoc. 2014;244(10):1164\u20131169."},{"issue":"4","key":"B17","series-title":"Vet Anaesth Analg","first-page":"406","article-title":"Maropitant prevented vomiting but not gastroesophageal reflux in anesthetized dogs premedicated with acepromazine-hydromorphone","volume":"41","year":"2014","unstructured":"Johnson RA. Maropitant prevented vomiting but not gastroesophageal reflux in anesthetized dogs premedicated with acepromazine-hydromorphone. Vet Anaesth Analg. 2014;41(4):406\u2013410."},{"issue":"4","key":"B18","series-title":"J Vet Emerg Crit Care (San Antonio)","first-page":"436","article-title":"Prospective, controlled, blinded, randomized crossover trial evaluating the effect of maropitant versus ondansetron on inhibiting tranexamic acid-evoked emesis","volume":"30","year":"2020","unstructured":"Kantyka ME, Meira C, Bettschart-Wolfensberger R, et al. Prospective, controlled, blinded, randomized crossover trial evaluating the effect of maropitant versus ondansetron on inhibiting tranexamic acid-evoked emesis. J Vet Emerg Crit Care (San Antonio). 2020;30(4):436\u2013441."},{"key":"B19","series-title":"J Vet Pharmacol Ther","first-page":"533","article-title":"Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs","volume":"31","year":"2008","unstructured":"Sedlacek HS, Ramsey DS, Boucher JF, et al. Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs. J Vet Pharmacol Ther. 2008;31:533\u2013537."},{"issue":"6","key":"B20","series-title":"J Am Anim Hosp Assoc","first-page":"338","article-title":"Assessing the efficacy of maropitant versus ondansetron in the treatment of dogs with parvoviral enteritis","volume":"54","year":"2018","unstructured":"Sullivan LA, Lenberg JP, Boscan P, et al. Assessing the efficacy of maropitant versus ondansetron in the treatment of dogs with parvoviral enteritis. J Am Anim Hosp Assoc. 2018;54(6):338\u2013343."},{"issue":"6","key":"B21","series-title":"J Vet Pharmacol Ther","first-page":"599","article-title":"Comparative efficacy of metoclopramide, ondansetron and maropitant in preventing parvoviral enteritis-induced emesis in dogs","volume":"40","year":"2017","unstructured":"Yalcin E, Keser GO. Comparative efficacy of metoclopramide, ondansetron and maropitant in preventing parvoviral enteritis-induced emesis in dogs. J Vet Pharmacol Ther. 2017;40(6):599\u2013603."},{"issue":"1","key":"B22","series-title":"BMC Vet Res","first-page":"244","article-title":"Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study","volume":"13","year":"2017","unstructured":"Kenward H, Elliott J, Lee T, et al. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. BMC Vet Res. 2017;13(1):244."},{"issue":"4","key":"B23","series-title":"Acta Anaesthesiol Scand","first-page":"470","article-title":"Assessment of postoperative nausea using a visual analogue scale","volume":"44","year":"2000","unstructured":"Boogaerts JG, Vanacker E, Seidel L, et al. Assessment of postoperative nausea using a visual analogue scale. Acta Anaesthesiol Scand. 2000;44(4):470\u2013474."},{"issue":"12","key":"B24","series-title":"Acad Emerg Med","first-page":"1304","article-title":"Use of the visual analog scale to rate and monitor severity of nausea in the emergency department","volume":"16","year":"2009","unstructured":"Meek R, Kelly AM, Hu XF. Use of the visual analog scale to rate and monitor severity of nausea in the emergency department. Acad Emerg Med. 2009;16(12):1304\u20131310."},{"issue":"11","key":"B25","series-title":"J Am Assoc Nurse Pract","first-page":"704","article-title":"The pathophysiology, incidence, impact, and treatment of opioid-induced nausea and vomiting","volume":"29","year":"2017","unstructured":"Mallick-Searle T, Fillman M. The pathophysiology, incidence, impact, and treatment of opioid-induced nausea and vomiting. J Am Assoc Nurse Pract. 2017;29(11):704\u2013710."},{"issue":"3","key":"B26","series-title":"Anesth Pain Med","first-page":"256","article-title":"Aprepitant prophylaxis effectively reduces preventing postoperative nausea and vomiting in patients receiving opioid-based intravenous patient-controlled analgesia","volume":"13","year":"2018","unstructured":"Yeo G, Lee MK, Kim H, et al. Aprepitant prophylaxis effectively reduces preventing postoperative nausea and vomiting in patients receiving opioid-based intravenous patient-controlled analgesia. Anesth Pain Med. 2018;13(3):256\u2013263."},{"issue":"7","key":"B27","series-title":"Clin Ther","first-page":"1216","article-title":"Intravenous ondansetron for the control of opioid-induced nausea and vomiting","volume":"21","year":"1999","unstructured":"Sussman G, Shurman J, Creed MR, et al. Intravenous ondansetron for the control of opioid-induced nausea and vomiting. Clin Ther. 1999;21(7):1216\u20131227."},{"issue":"12","key":"B28","series-title":"Am J Vet Res","first-page":"1576","article-title":"Effect of maropitant, a neurokinin 1 receptor antagonist, on anesthetic requirements during noxious visceral stimulation in dogs","volume":"72","year":"2011","unstructured":"Boscan P, Monnet E, Mama K, et al. Effect of maropitant, a neurokinin 1 receptor antagonist, on anesthetic requirements during noxious visceral stimulation in dogs. Am J Vet Res. 2011;72(12):1576\u20131579."},{"issue":"2","key":"B29","series-title":"Vet Anaesth Analg","first-page":"201","article-title":"Effect of epidural and intravenous use of the neurokinin-1 (NK-1) receptor antagonist maropitant on the sevoflurane minimum alveolar concentration (MAC) in dogs","volume":"39","year":"2012","unstructured":"Alvillar BM, Boscan P, Mama KR. Effect of epidural and intravenous use of the neurokinin-1 (NK-1) receptor antagonist maropitant on the sevoflurane minimum alveolar concentration (MAC) in dogs. Vet Anaesth Analg. 2012;39(2):201\u2013205."},{"key":"B30","series-title":"Int J Appl Res Vet Med","first-page":"228","article-title":"Cerenia prevents perioperative nausea and vomiting and improves recovery in dogs undergoing routine surgery","volume":"12","year":"2014","unstructured":"Ramsey D, Fleck T, Berg T, et al. Cerenia prevents perioperative nausea and vomiting and improves recovery in dogs undergoing routine surgery. Int J Appl Res Vet Med. 2014;12:228\u2013237."},{"key":"B31","series-title":"Am J Vet Res","first-page":"48","article-title":"Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs","volume":"68","year":"2007","unstructured":"de la Puente-Redondo VA, Tilt N, Rowan TG, et al. Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. Am J Vet Res. 2007;68:48\u201356."},{"key":"B32","series-title":"Anesth Analg","first-page":"1884","article-title":"Risk factors for postoperative nausea and vomiting","volume":"102","year":"2006","unstructured":"Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth Analg. 2006;102:1884\u20131898."},{"issue":"6","key":"B33","series-title":"J Vet Intern Med","first-page":"1452","article-title":"Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs","volume":"24","year":"2010","unstructured":"Rau SE, Barber LG, Burgess KE. Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs. J Vet Intern Med. 2010;24(6):1452\u20131457."},{"key":"B34","series-title":"J Vet Pharmacol Ther","first-page":"220","article-title":"Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats","volume":"31","year":"2008","unstructured":"Hickman MA, Cox SR, Mahabir S, et al. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther. 2008;31:220\u2013229."},{"issue":"Suppl 1","key":"B35","series-title":"Eur J Cancer Clin Oncol","first-page":"S75","article-title":"The metabolism of ondansetron","volume":"25","year":"1989","unstructured":"Saynor DA, Dixon CM. The metabolism of ondansetron. Eur J Cancer Clin Oncol. 1989;25(Suppl 1):S75\u2013S77."},{"key":"B36","series-title":"J Vet Pharmacol Ther","first-page":"348","article-title":"Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats","volume":"37","year":"2014","unstructured":"Quimby JM, Lake RC, Hansen RJ, et al. Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats. J Vet Pharmacol Ther. 2014;37:348\u2013353."},{"issue":"2","key":"B37","series-title":"J Vet Pharmacol Ther","first-page":"199","article-title":"Pharmacokinetic modeling and Monte Carlo simulation of ondansetron following oral administration in dogs","volume":"38","year":"2015","unstructured":"Baek IH, Lee BY, Kang J, et al. Pharmacokinetic modeling and Monte Carlo simulation of ondansetron following oral administration in dogs. J Vet Pharmacol Ther. 2015;38(2):199\u2013202."},{"issue":"8","key":"B38","series-title":"J Pharm Pharmacol","first-page":"774","article-title":"Clinical pharmacokinetics of ondansetron. A review","volume":"48","year":"1996","unstructured":"Simpson KH, Hicks FM. Clinical pharmacokinetics of ondansetron. A review. J Pharm Pharmacol. 1996;48(8):774\u2013781."},{"key":"B39","series-title":"J Vet Pharmacol Ther","first-page":"336","article-title":"The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs","volume":"30","year":"2007","unstructured":"Benchaoui HA, Cox SR, Schneider RP, et al. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. J Vet Pharmacol Ther. 2007;30:336\u2013344."}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/260\/S1\/javma.21.02.0082.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/260\/S1\/javma.21.02.0082.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/260\/S1\/javma.21.02.0082.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T11:12:17Z","timestamp":1727435537000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/260\/S1\/javma.21.02.0082.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":39,"journal-issue":{"issue":"S1"},"URL":"https:\/\/doi.org\/10.2460\/javma.21.02.0082","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,15]]}}}